Global Prostate Cancer Therapeutics Industrial and Market studies to 2020
"Global
Prostate Cancer Therapeutics Market to 2020"
The Report covers current Market Trends, Analysis, Forecast, Review,
Share, Size, Growth, Effect.
Description-
Global
Prostate Cancer Therapeutics Market Overview
The
prostate cancer drugs market is expected to nearly double by 2020,
due to the introduction of new, more expensive drugs. Prostate Cancer
is the most frequently diagnosed cancer in men. In terms of loss of
life from any disease, prostate cancer ranks eleventh; and it ranks
sixth in terms of cancer–related mortality in men. The prostate
cancer market has a huge demand for new and novel drugs that address
unmet needs such as improved survival time, less toxicity, increased
progression free survival, increased effectiveness, and lower cost.
The global market for the prostate cancer therapeutics market is
increasing, driven primarily by the growth in the hormone–refractory
prostate cancer therapeutics market. Although, the prostate cancer
market faces some hindrances such as the high cost of prostate cancer
drugs, the market for prostate cancer drugs is likely to rise in the
future.
Global
Prostate Cancer Drugs Analysis: Zytiga was the leading prostate
cancer drugs in 2014 being followed by Xtandi drugs. In prostate
cancer drugs market, Leuplin and Zoladex stand at the third and
fourth position respectively in 2014, while Lupron stands at the
fifth position in the same year. Bayer's cancer drug Xofigo is also
increasing its market share. Decapeptyl, Taxotere, Jevtana and
Provenge are the other popular prostate cancer drugs in the global
market.
Renub
Research report titled “Global Prostate Cancer Therapeutics Market
to 2020” provides a comprehensive assessment of the fast–evolving,
high–growth of Prostate Cancer Therapeutics Market. This 80 page
report with35 Figures and 2 Tables analyses the Prostate Cancer
Therapy Drugs Market, driving factors and challenges for prostate
cancer market landscape.
The
report covers the following:
1.
Global Prostate Cancer – Hormonal Therapy Drugs Market
•
Luteinizing
Hormone–Releasing Hormone (LHRH) Antagonists
1.
Zytiga
2.
Gonax
•
Luteinizing
Hormone–Releasing Hormone (LHRH) Analogs
1.
Lupron
2.
Zoladex
3.
Decapeptyl
4.
Eligard
5.
Vantas
6.
Leuplin
•
Anti–Androgens
1.
Casodex
2.
Xtandi or MDV3100
3.
Xtandi US or MDV3100
Comments
Post a Comment